Rituximab Disappoints in Sjögren Syndrome Medscape The investigators observed no significant differences at 24 weeks between groups receiving rituximab or placebo in any clinical endpoints or symptoms, including pain, fatigue, salivary flow, and tear production. The drug was administered in 2 infusions ... |
